However, it is promising that having active anticancer response, rich immune network with CD8 cells and high PD-1-PD-L1 axis and, probably, tumour mutational burden (TMB) patients with COPD could have benefit from immunotherapy with ICIs. Here, CD274 is linked to neoplasm.